iBio (IBIO) Research & Development (2009 - 2026)
iBio (IBIO) recorded Research & Development of $8.56 million in fiscal Q4 2026 (quarter ended Jun 30, 2026), up 165.5% from $3.22 million a year earlier and up 163.0% from the prior quarter.
iBio (IBIO) Research & Development (2009 - 2026) Analysis & Trends
For FY2026 (ended Jun 30, 2026), iBio reported Research & Development of $19.64 million, up 136.3% from FY2025.
- Annual Research & Development has a five-year compound annual growth rate of 14.5% (FY2021 to FY2026).
- Across earlier fiscal years, Research & Development came in at $8.31 million in FY2025 (+60.3%), $5.19 million in FY2024 (-49.8%), $10.33 million in FY2023 (+5.1%) and $9.83 million in FY2022 (-1.6%).
- The fiscal Q4 2026 figure is the highest quarterly Research & Development in data going back to fiscal Q1 2011.
- On a year-over-year basis, Research & Development has increased for seven consecutive quarters, with growth averaging 104.2% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 182.8% in fiscal Q4 2025, against a decline of 65.8% in fiscal Q3 2024 at the low end.
- Per Business Quant, the preceding three fiscal quarters came in at $3.25 million (Q3 2026), $4.28 million (Q2 2026) and $3.55 million (Q1 2026).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.02 Bn |
| 10 | iBio | 118.23 Mn | -174.02 Mn | - | 6.65 Mn |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 6.65 Mn |
| Jun 30, 2026 | 8.56 Mn |
| Mar 31, 2026 | 3.25 Mn |
| Dec 31, 2025 | 4.28 Mn |
| Sep 30, 2025 | 3.55 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 904,000.00 |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 1.61 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.55 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 3.27 Mn |
| Dec 31, 2021 | 1.86 Mn |
iBio Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=IBIO&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "IBIO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=IBIO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();